QSimulate

Based in the US, Quantum Simulation Technologies, Inc. specializes in quantum simulations to enhance drug design and materials discovery, utilizing advanced computing technology to streamline research processes across multiple industries. Founded in 2018 in Boston, US, Quantum Simulation Technologies, Inc. focuses on providing advanced quantum simulation solutions.

In November 2025, QSimulate raised USD 11 million in seed funding from Embark Ventures. The company is led by CEO and founder Toru Shiozaki, who has played a pivotal role in shaping its strategic direction. QSimulate specializes in quantum simulations designed to enhance drug design processes and materials discovery. Their core offerings leverage advanced quantum computing technology to accelerate research and development in various industries, particularly in life sciences and materials design.

The software solutions provided by QSimulate facilitate high-throughput data-driven discoveries, allowing clients to tackle complex industrial-scale problems. Their products primarily target pharmaceutical companies, biotech firms, and research institutions, enabling them to optimize drug lead identification and accelerate the development of new materials, with a presence in key global markets including North America, Europe, and Asia. QSimulate generates revenue through a B2B model, providing quantum simulation software and services to industry clients under various transaction structures. The company offers subscription-based pricing plans that allow clients to access their software solutions for set periods, catering to different client needs from small biotech startups to large pharmaceutical corporations.

Additionally, QSimulate may establish strategic partnerships to enhance its service offerings, driving revenue through collaborative projects focused on drug discovery and materials science. This revenue model aligns with the growing demand for innovative computational tools in R&D. The company plans to utilize the November 2025 funding to grow its operations and further develop its quantum-based simulation platform for drug discovery.